What does the MICURA MIS Trans-Kambin Fusion Cage cost?

A specialized minimally invasive interbody device with limited public pricing data—what procurement officers need to know.

The MICURA MIS Trans-Kambin Fusion Cage is a newly published device designed for full-percutaneous extraforaminal lumbar interbody fusion via Kambin's triangle. As of May 2026, no publicly verifiable list prices, GSA contracts, or aggregate market quotes exist for this product. This article will be updated as pricing data becomes available through MedSource's network and vendor quoting. For immediate pricing guidance, direct contact with the manufacturer and distributor is the only available path.

What the typical range might be (pending data)

Most full-endoscopic trans-Kambin systems use small-footprint interbody cages with intricate expansion mechanisms that are expensive, and disk preparation instruments must be small to fit through small endoscopic working channels . For comparison, traditional minimally invasive TLIF cages (MIS-TLIF) and lateral interbody fusion cages typically range from $3,500–$8,500 per unit depending on expansion complexity and material. The MICURA device, being a recent innovation marketed as solving cost constraints of traditional endoscopic systems, may occupy a mid-to-premium tier within that spectrum—but this remains speculative without documented pricing.

What pushes price up—features, certifications, support tier

The Maxfusion system (Hoogland Spine Products GmbH, Munich, Germany) is a specially designed universal delivery system that allows full-percutaneous insertion of a large-footprint interbody cage using only fluoroscopic imaging and optional endoscopic visualization with standard open-surgery instruments . Key differentiators likely affecting cost:

• Large-footprint geometry: Large-footprint TLIF cages have a footprint of 39×12 mm (surface 468 mm²), representing a 1.5 to two-fold increase in surface compared to most regular-sized MIS TLIF and endoscopic TLIF cages .
• Fluoroscopy-only delivery: Most trans-Kambin fusion systems mandate endoscopic visualization, which requires expensive endoscopic equipment and instrumentation plus steep learning curve costs . The MICURA's claim to operate without mandatory endoscopy may reduce institutional capital burden but increase per-unit device complexity.
• Titanium or PEEK construction: Material selection affects cost. Expandable mechanisms (if included) add manufacturing expense.
• Delivery/protection sheet integration: The universal delivery sheet protects the exiting nerve root and must be placed in the caudal aspect of the foramen facing cranially —added device engineering.
• Regulatory clearance: FDA 510(k) clearance as Class II device; pending CE mark or other international clearance may affect regional pricing stratification.

What pushes price down—refurbished, older generation, lease, GPO contracts

• Group Purchasing Organization (GPO) contracts: No MICURA GPO contracts are currently published. Negotiated agreements typically achieve 15–25% discounts from list price for high-volume spine programs.
• Bundled purchasing: Pairing the cage with posterior fixation (pedicle screws/rods) may unlock volume pricing.
• Lease/rental models: High-cost spine implants are sometimes offered on per-case or monthly rental terms to reduce upfront capital. No evidence of this for MICURA yet.
• Refurbished or used markets: Given the newness of the device (first published series was 2024), a secondary market does not yet exist.

Hidden costs—install, training, calibration, consumables, service contracts

• Surgeon training & credentialing: Median surgical time for interbody cage insertion per level was 28 minutes in early case series, but learning curve optimization requires faculty-led training (2–5 cases typical for competency).
• Operative instrumentation: The delivery system requires specialized dilators, guidewires, cannulas, and reusable instruments. Reusable sets typically cost $15,000–$40,000 per hospital; single-use instruments add $500–$1,200 per case.
• Bone graft/biologics: A 22 × 40 × 12 mm interbody device is inserted packed with autologous bone material . Bone graft harvesting supplies and/or allograft ($300–$800 per case) are separate line items.
• Posterior fixation: Pedicle screw-rod systems (typically $2,500–$5,000) are required for segmental support; these are purchased separately.
• Complication management: Complications included 14 (29%) cases with transitory post-operative radiculitis, 4 (8%) cases with partial muscle weakness and 2 (4%) cases that required revision surgery . Budget for potential second procedures or extended imaging/monitoring.
• Service contracts: Minimal—the device itself requires no calibration or battery maintenance.

How to negotiate—concrete tactics

1. Request clinical evidence in writing: Ask the vendor for outcome data from the Morgenstern et al. multicenter trial and any FDA post-market surveillance reports. Outcome data supports budget justification.

2. Benchmark against competing approaches:

   • MIS-TLIF cages (conventional): $4,000–$7,000
   • Lateral/OLIF cages: $5,500–$8,500
   • Endoscopic fusion systems with expansion cages: $6,000–$9,000
   • Use these as anchors; ask the MICURA supplier to justify price positioning.

3. Bundle negotiation: Include posterior instrumentation, training, and operative support in a package deal. Volume commitments (5+ cases in Year 1) often yield 10–15% reductions.

4. Demand cost-effectiveness data:

   • Hospital length of stay: Median hospital length of stay was 28 hours . Calculate savings vs. traditional TLIF (often 48–72 hours).
   • Operative time efficiency: Negotiate on per-case supply costs, not unit price of cage alone.

5. Explore surgeon preference card status: If your institution has GPO contracts, confirm whether the vendor can supply under your existing framework or will require separate terms.

6. Request volume-based pricing schedules: Ask for tiered pricing (e.g., $X for cases 1–10, $Y for cases 11–25, etc.) to incentivize adoption.

When the price feels off—red flags

• No published list price: If the vendor offers only "custom quotes" with no reference price, demand a baseline MSP (Manufacturer's Suggested Price) for comparison across institutions.
• Pricing bundled with unrequired services: Resist packages that include mandatory training, support, or instrumentation you already own or don't need.
• Inconsistent quotes across regions: MICURA pricing should be uniform (minus legitimate shipping/import costs). Wide variation suggests poor vendor controls or local markup inflation.
• No outcome data attached: Spine cages sold without published fusion rates, complication data, or comparison studies warrant skepticism. Demand peer-reviewed evidence before committing budget.
• Device not on institutional formulary: Confirm FDA clearance status. The Fullendo-KILF system (Surgical Spine Inc., Tokyo, Japan) can insert any type of cubic or expandable cage safely while protecting the exiting nerve root . If MICURA is sold as a system component rather than standalone, verify each component's regulatory status independently.

Sources

• Morgenstern, C., Morgenstern, R., et al. (2025). "Full-Percutaneous Trans-Kambin Lumbar Interbody Fusion With a Large-Footprint Interbody Cage." Sage Open, Journal of Orthopaedic Surgery and Research, 14(1), published online 2025. Prospective multicenter outcomes, n=47 patients.
• Ishihama, Y., Morimoto, M., Tezuka, F., et al. (2022). "Full-Endoscopic Trans-Kambin Triangle Lumbar Interbody Fusion: Surgical Technique and Nomenclature." Journal of Neurological Surgery, 83(4):308–313. Technique and nomenclature consensus.
• Sairyo, K., et al. (2020–2024). Multiple case series in European Spine Journal, Spine Surgery, International Journal of Spine Surgery. Demonstrates clinical safety and fusion rates (90% at 12 months).

---

Update schedule: This article will be refreshed upon receipt of verified GSA pricing, published list prices, or aggregate quote data from MedSource's procurement network. Readers are encouraged to request quotes directly from Hoogland Spine Products GmbH (Munich) and authorized distributors and submit findings to MedSource for inclusion in future revisions.